We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Egis Pharmaceuticals

Pharmaceutical > Hungary > Egis Pharmaceuticals
Change Company
Egis Pharmaceuticals

EGIS Pharmaceuticals Plc (Egis) is a Hungary-based pharmaceutical company focused on the research, development and commercialization of pharmaceuticals and active pharmaceutical ingredients (API). The company is principally focused on the development of human pharmaceuticals for the treatment of cardiovascular, central nervous system, respiratory and digestive system disorders. The company sells its products in several countries across the

Read more »
EGIS Pharmaceuticals Plc (Egis) is a Hungary-based pharmaceutical company focused on the research, development and commercialization of pharmaceuticals and active pharmaceutical ingredients (API). The company is principally focused on the development of human pharmaceuticals for the treatment of cardiovascular, central nervous system, respiratory and digestive system disorders. The company sells its products in several countries across the world through its subsidiary companies network. EGIS predominantly operates in the Eastern Europe and has presence across countries such as Russia, Ukraine, the Czech Republic, Poland, Romania and Slovakia. The company is headquartered in Budapest, Hungary.

Buy all financials of Egis Pharmaceuticals

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

income statement

Sales HUF mil
Gross Profit HUF mil
EBIT HUF mil
Net Profit HUF mil
ROE %
EBIT Margin %
Net Margin %
            110,800 117,176 109,192 116,142 118,915    
            59,692 54,322 57,554 64,350 66,709    
            15,965 7,789 8,597 14,040 15,512    
            16,883 7,622 12,044 13,751 16,783    
            18.1% 7.27% 10.6% 10.9% 11.9%    
            14.4% 6.65% 7.87% 12.1% 13.0%    
            15.2% 6.50% 11.0% 11.8% 14.1%    

balance sheet

            116,388 125,842 139,926 157,904 174,542    
            52,168 58,019 63,700 68,948 75,028    
            64,220 67,823 76,226 88,956 99,514    
            101,541 108,049 119,229 132,757 149,122    
            14,847 17,793 20,697 25,147 25,420    
            1,312 1,742 3,606 4,081 4,205    
            13,535 16,051 17,091 21,066 21,215    
            -0.199 -0.492 -0.109 -0.912 -0.620    
            -0.043 -0.066 -0.015 -0.150 -0.099    
...           12.3% 309% 54.2% 61.8% 13.3%    

cash flow

... ... ...       13,345 15,556 15,308 22,729 14,379    
... ... ...       -10,268 -12,217 -19,642 -3,042 -18,702    
... ... ...       -2,941 -4.00 785 -1,187 -942    
... ... ...       136 3,335 -3,549 18,500 -5,265    

valuation

            7.79 7.79 7.79 7.79 7.79    
            30,000 22,990 11,270 19,600 22,300    
            2,169 979 1,547 1,766 2,156    
            13,042 13,878 15,314 17,051 19,153    
            13.8 23.5 7.29 11.1 10.3    
            2.30 1.66 0.736 1.15 1.16    
...           51.3% -54.9% 58.0% 14.2% 22.0%    
...           18.8% 6.41% 10.3% 11.3% 12.3%    

Download Data
income statement Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

income statement

Sales HUF mil
Cost of Goods & Services HUF mil
Gross Profit HUF mil
EBITDA HUF mil
Depreciation HUF mil
EBIT HUF mil
Financing Cost HUF mil
Extraordinary Cost HUF mil
Pre-Tax Profit HUF mil
Tax HUF mil
Minorities HUF mil
Net Profit HUF mil
            110,800 117,176 109,192 116,142 118,915    
            51,108 62,854 51,638 51,792 52,206    
            59,692 54,322 57,554 64,350 66,709    
            21,996 14,573 16,696 21,851 23,809    
            6,031 6,784 8,099 7,811 8,297    
            15,965 7,789 8,597 14,040 15,512    
            193 2,623 1,093 1,874 423    
            -3,390 -2,698 -5,232 -2,359 -2,666    
            19,162 7,864 12,736 14,525 17,755    
            2,278 242 692 774 972    
            0.000 0.000 0.000 0.000 0.000    
            16,883 7,622 12,044 13,751 16,783    

growth rates

...           18.3% 5.75% -6.81% 6.36% 2.39%    
...           49.1% -33.7% 14.6% 30.9% 8.96%    
...           62.2% -51.2% 10.4% 63.3% 10.5%    
...           54.9% -59.0% 62.0% 14.0% 22.2%    
...           51.3% -54.9% 58.0% 14.2% 22.0%    

ratios

            18.1% 7.27% 10.6% 10.9% 11.9%    
...           18.8% 7.97% 11.9% 12.9% 14.4%    
            53.9% 46.4% 52.7% 55.4% 56.1%    
            19.9% 12.4% 15.3% 18.8% 20.0%    
            14.4% 6.65% 7.87% 12.1% 13.0%    
            15.2% 6.50% 11.0% 11.8% 14.1%    
...           12.3% 309% 54.2% 61.8% 13.3%    
            -0.199 -0.492 -0.109 -0.912 -0.620    

Download Data
balance sheet Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

balance sheet

            52,168 58,019 63,700 68,948 75,028    
            40,970 45,275 51,513 57,189 63,508    
            678 696 3,865 4,286 4,089    
            64,220 67,823 76,226 88,956 99,514    
            29,662 29,866 33,790 38,957 38,768    
            20,960 17,874 23,564 19,830 30,176    
            4,952 8,287 4,738 23,072 17,973    
            116,388 125,842 139,926 157,904 174,542    
            101,541 108,049 119,229 132,757 149,122    
            0.000 0.000 0.000 0.000 0.000    
            14,847 17,793 20,697 25,147 25,420    
            1,312 1,742 3,606 4,081 4,205    
            0.000 1,068 2,825 3,029 2,989    
            13,535 16,051 17,091 21,066 21,215    
            583 48.0 95.0 111 221    
            8,294 8,905 16,244 19,649 19,756    
            116,388 125,842 139,926 157,904 174,542    

growth rates

...           14.5% 8.12% 11.2% 12.8% 10.5%    
...           18.8% 6.41% 10.3% 11.3% 12.3%    
...           93.2% 64.1% -74.6% 996% -25.9%    
...           -77.2% 91.4% 162% 7.53% 2.23%    

ratios

            583 1,116 2,920 3,140 3,210    
            -4,369 -7,171 -1,818 -19,932 -14,763    
            42,328 38,835 41,110 39,138 49,188    
            94,496 96,854 104,810 108,086 124,216    
            -0.043 -0.066 -0.015 -0.150 -0.099    
...           12.3% 309% 54.2% 61.8% 13.3%    

Download Data
cash flow Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

cash flow

            16,883 7,622 12,044 13,751 16,783    
            6,031 6,784 8,099 7,811 8,297    
... ... ...       -5,110 -2,343 -2,560 -805 -651    
... ... ...       -4,460 3,493 -2,275 1,972 -10,050    
... ... ...       13,345 15,556 15,308 22,729 14,379    
... ... ...       -10,447 -12,454 -13,680 -14,070 -14,508    
... ... ...       179 237 -5,962 11,028 -4,194    
... ... ...       -10,268 -12,217 -19,642 -3,042 -18,702    
... ... ...       -1,972 533 1,804 220 70.0    
... ... ...       -2,941 -4.00 785 -1,187 -942    
... ... ...       136 3,335 -3,549 18,500 -5,265    

ratios

            69.0 55.7 78.8 62.3 92.6    
            212 173 239 275 271    
            59.2 51.7 115 138 138    
            222 177 203 198 226    
            22,915 14,406 20,143 21,562 25,080    
            2,943 1,850 2,587 2,769 3,221    
            10.2 12.4 4.36 7.08 6.92    
... ... ...       3,077 3,339 -4,334 19,687 -4,323    

Download Data
other data Unit
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

other data

            15.5% 6.29% 9.06% 9.23% 10.1%    
            53.9% 46.4% 52.7% 55.4% 56.1%    
            11.9% 3.08% 5.43% 5.33% 5.47%    
... ... ...       9.43% 10.6% 12.5% 12.1% 12.2%    

Download Data
EGIS Pharmaceuticals at a Glance

EGIS Pharmaceuticals (Egis) is a Hungary-based pharmaceutical company focused on the research, development and commercialization of pharmaceuticals and active pharmaceutical ingredients (API). The company is principally focused on the development of human pharmaceuticals for the treatment of cardiovascular, central nervous system, respiratory and digestive system

Read more »

EGIS Pharmaceuticals (Egis) is a Hungary-based pharmaceutical company focused on the research, development and commercialization of pharmaceuticals and active pharmaceutical ingredients (API). The company is principally focused on the development of human pharmaceuticals for the treatment of cardiovascular, central nervous system, respiratory and digestive system disorders. The company sells its products in several countries across the world through its subsidiary companies network. EGIS predominantly operates in the Eastern Europe and has presence across countries such as Russia, Ukraine, the Czech Republic, Poland, Romania and Slovakia. The company is headquartered in Budapest, Hungary.

This report offers a summary of the company's performance in 2000-2013. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Egis Pharmaceuticals invested total of HUF 15,263 mil in 2012, down 0.670% when compared to the previous year. Historically, company's investments reached an all time high of HUF 15,366 mil in 2011 and an all time low of HUF 7,122

Read more »

Egis Pharmaceuticals invested total of HUF 15,263 mil in 2012, down 0.670% when compared to the previous year. Historically, company's investments reached an all time high of HUF 15,366 mil in 2011 and an all time low of HUF 7,122 mil in 2003.

When compared to total sales, investments reached 11.5% in 2012, down from 11.9% seen in the previous year. This is compared to 12.1% seen on average in the last five years.

As far as Egis Pharmaceuticals's peers are concerned, Gedeon Richter invested HUF 26,617 mil, or 8.15% of its sales in 2012. The comparable figures for Krka are HUF 145 mil and 12.7% respectively and HUF 13.6 mil and 0.188% at Sanofi-Aventis Czech Republic on 2012 numbers.

You can see all the company’s data at Egis Pharmaceuticals Profile, or you can download a report on the company in the report section.

Egis Pharmaceuticals's net debt reached HUF -43,021 mil and accounted for -0.240 of equity at the end of 2012. The ratio is down 19.6% when compared to the previous year.

Historically, the firm’s net debt to equity reached an

Read more »

Egis Pharmaceuticals's net debt reached HUF -43,021 mil and accounted for -0.240 of equity at the end of 2012. The ratio is down 19.6% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of < -0.001 in 2003 and an all time low of -0.240 in 2012.

When compared to EBITDA, net debt amounted to -1.41x at the end of the year. The ratio reached an all time high of -0.001 in 2003 and an all time low of -1.41 in 2012.

As far as Egis Pharmaceuticals's peers are concerned, Gedeon Richter posted net debt to equity of -0.054x and -0.373x when compared to EBITDA at the end of 2012. Krka ended the year 2012 with a net debt at 0.003x of equity and 0.012x when compared to its EBITDA while Krka had net debt at 0.003x of equity and 0.012x to EBITDA at the end of the year.

You can see all the company’s data at Egis Pharmaceuticals Profile, or you can download a report on the company in the report section.

Egis Pharmaceuticals's total assets reached HUF 208,238 mil at the end of 2012, up 8.14% when compared to the previous year.

Current assets amounted to HUF 125,990 mil, or 60.5% of total assets while cash reached HUF 45,929 mil at the end of 2012.

Read more »

Egis Pharmaceuticals's total assets reached HUF 208,238 mil at the end of 2012, up 8.14% when compared to the previous year.

Current assets amounted to HUF 125,990 mil, or 60.5% of total assets while cash reached HUF 45,929 mil at the end of 2012.

On the other hand, total debt reached HUF 2,908 mil at the year-end, or 60.5% of total assets while firm's equity amounted to HUF 179,490 mil. As a result, net debt reached HUF -43,021 mil at the end of 2012 and accounted for -24.0% of equity.

You can see all the company’s data at Egis Pharmaceuticals Profile, or you can download a report on the company in the report section.

Egis Pharmaceuticals's operating cash flow reached HUF 26,342 mil in 2012, down 0.697% when compared to the previous year. Historically, the firm’s operating cash flow reached an all time high of HUF 26,527 mil in 2011 and an all time

Read more »

Egis Pharmaceuticals's operating cash flow reached HUF 26,342 mil in 2012, down 0.697% when compared to the previous year. Historically, the firm’s operating cash flow reached an all time high of HUF 26,527 mil in 2011 and an all time low of HUF 6,037 mil in 2003.

Egis Pharmaceuticals's total investments reached HUF 14,896 mil and accounted for 11.5% of sales in 2012. This is compared to 12.1% seen on average in the last five years.

Since cash from financing amounted to HUF -1,074 mil, net cash the company generated in 2012 reached HUF 45,929 mil.

You can see all the company’s data at Egis Pharmaceuticals Profile, or you can download a report on the company in the report section.

See all charts of the company »
Egis's net profit rose 36.4% to HUF 18,531 mil in 2012
Egis's net profit rose 36.4% to HUF 18,531 mil in 2012
Egis's Net Debt/EBITDA fell 11.4% to -1.41 in 2012
Egis's Cash & Cash Equivalents rose 29.2% to HUF 45,929 mil in 2012
Egis's Capital Expenditures fell 0.670% to HUF 15,263 mil in 2012
Egis's Total Cash From Operations fell 0.697% to HUF 26,342 mil in 2012
Egis's Net Margin rose 32.4% to 14.0% in 2012
Egis's ROCE rose 31.7% to 14.1% in 2012